Skip to content
Sample Page
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Posted Date:
May 28, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea Pharmaceutica International Ltd, Allschwil
May 28, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Basilea Pharmaceutica International Ltd, Allschwil
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Basilea Pharmaceutica International Ltd, Allschwil
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Basilea Pharmaceutica International Ltd, Allschwil
March 23, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea Pharmaceutica International Ltd, Allschwil
February 25, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Basilea Pharmaceutica International Ltd, Allschwil
February 17, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Basilea Pharmaceutica International Ltd, Allschwil
February 9, 2026
